The recent e-rickshaw shutdowns revealed that the real security flaw wasn’t in the battery management apps but in battery ...
Learn how CDs pay compound interest and how it affects their annual percentage yield (APY) to maximize your savings strategy ...
Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...
On April 15, 2026, the U.S. Food and Drug Administration (“FDA”) announced that it will convene a public meeting of the Pharmacy Compounding Advisory Committee (“PCAC”) on July 23-24, 2026, to ...
On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for ...
The Food and Drug Administration on April 30 proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...
The FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, the latest move in a monthslong crackdown on the compounded GLP-1 market. The 503B bulks list ...
With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory committee to discuss allowing compounders to make molecules despite earlier ...
The Food and Drug Administration is taking the first step toward potentially allowing compounding pharmacies to produce seven peptides that are currently restricted because of the agency’s previous ...
A mystery drug has shown promise for Parkinson’s disease, improving the mobility and balance of mice with Parkinson’s-like symptoms. The drug works by boosting the brain’s waste disposal system to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results